Creative Biostructure provides virus-like particles (VLPs) products which are produced from recombinant E. coli, yeast, insect cells, or HEK293 cells. Our product line includes a wide variety of virus families including Parvoviridae (e.g. adeno-associated virus), Retroviridae (e.g. HIV), Flaviviridae (e.g. Hepatitis C virus) and bacteriophages (e.g. Qβ, AP205).
Virus-like particles (VLPs) have evolved to become a widely accepted technology, especially in the field of vaccinology. In fact, some VLP-based vaccines are currently used as commercial medical products, and other VLP-based products are at different stages of clinical study. Several remarkable advantages have been achieved in the development of VLPs as gene therapy tools and new nanomaterials. In recent years, the technologies develop very fast that are used to characterize the structural integrity, stability, and components, including the encapsidated nucleic acids, of newly synthesized VLPs. Moreover, some of the modifications that are required to construct VLP-based carriers of viral origin with defined properties can be provided.
The self-assembly is the most important part for VLP formation. Scientists of Creative Biostructure have deep understanding of VLP assembly based on the knowledge of viral assembly and long-term project experience. In vitro, assembly of VLPs competes with aggregation. With excellent skills in antigen purification, our scientists can prevent the formation of aggregates while assembly is going.
VLPs are used throughout drug and antibody discovery and characterization, and have been integrated into a wide variety of existing platforms.
Creative Biostructure holds good stocks of all our antigens to ensure a rapid delivery service worldwide. Using our optimized production process, custom VLPs are engineered to incorporate high concentrations of specified capsid. We like to be in touch with our customers so please feel free to contact us for a formal quote.